In the latest trading session,, 0.42 million UroGen Pharma Ltd (NASDAQ:URGN) shares changed hands as the company’s beta touched 0.70. With the company’s most recent per share price at $10.82 changing hands around $0.95 or 9.63% at last look, the market valuation stands at $498.74M. URGN’s current price is a discount, trading about -91.31% off its 52-week high of $20.70. The share price had its 52-week low at $8.94, which suggests the last value was 17.38% up since then. When we look at UroGen Pharma Ltd’s average trading volume, we note the 10-day average is 0.48 million shares, with the 3-month average coming to 423.02K.
Analysts gave the UroGen Pharma Ltd (URGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended URGN as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. UroGen Pharma Ltd’s EPS for the current quarter is expected to be -0.8.
UroGen Pharma Ltd (NASDAQ:URGN) trade information
Instantly URGN is in green as seen in intraday trades today. With action 12.01%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 1.60%, with the 5-day performance at 12.01% in the green. However, in the 30-day time frame, UroGen Pharma Ltd (NASDAQ:URGN) is -5.50% down. Looking at the short shares, we see there were 5.06 million shares sold at short interest cover period of 10.68 days.
The consensus price target for the stock as assigned by Wall Street analysts is 40, meaning bulls need an upside of 72.95% from its recent market value. According to analyst projections, URGN’s forecast low is 22 with 60 as the target high. To hit the forecast high, the stock’s price needs a -454.53% plunge from its current level, while the stock would need to soar -103.33% for it to hit the projected low.
UroGen Pharma Ltd (URGN) estimates and forecasts
Year-over-year growth is forecast to reach 34.62% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 22.7M. 7 analysts are of the opinion that UroGen Pharma Ltd’s revenue for the current quarter will be 24.66M. The company’s revenue for the corresponding quarters a year ago was 18.78M and 21.85M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 20.89%. The estimates for the next quarter sales put growth at 12.85%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 10.39%. The 2025 estimates are for UroGen Pharma Ltd earnings to increase by 1.29%.
URGN Dividends
UroGen Pharma Ltd is expected to release its next quarterly earnings report on 2025-Mar-09.
UroGen Pharma Ltd (NASDAQ:URGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.40% of UroGen Pharma Ltd shares while 87.18% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.18%. There are 87.18% institutions holding the UroGen Pharma Ltd stock share, with RTW INVESTMENTS, LP the top institutional holder. As of 2024-06-30, the company held 9.661% of the shares, roughly 3.56 million URGN shares worth $59.69 million.
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 8.9621% or 3.3 million shares worth $55.37 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Russell 2000 ETF and Fidelity Salem Street Trust-Fidelity Small Cap Index Fund . With 998.29 shares estimated at $10.7 million under it, the former controlled 2.17% of total outstanding shares. On the other hand, Fidelity Salem Street Trust-Fidelity Small Cap Index Fund held about 0.82% of the shares, roughly 375.71 shares worth around $4.03 million.
